A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries.

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus that has never been identified in humans before. COVID-19 caused at the time of writing of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including two-third in Europe. In this context, Oncology Departments of the affected countries had to adapt quickly their health system care and establish new organizations and priorities. Thus, numerous recommendations and therapeutic options have been reported to optimize therapy delivery to patients with chronic disease and cancer. Obviously, while these cancer care recommendations are immediately applicable in Europe, they may not be applicable in certain emerging and low- and middle-income countries (LMICs). In this review, we aimed to summarize these international guidelines in accordance with cancer types, making a synthesis for daily practice to protect patients, staff and tailor anti-cancer therapy delivery taking into account patients/tumour criteria and tools availability. Thus, we will discuss their applicability in the LMICs with different organizations, limited means and different constraints.

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest statement A.I. declares the following relevant financial activities outside the submitted work: has received Grants from Transgene, Sanofi, Air Liquide, Nutritheragene; has received travel funding from Leo Pharma; Grant research support and travel funding from Carthera. J.G. declare the following financial personnal fees for activities outside the submitted work or served as consultant or advisory board/ has received symposium and travel funding from: Roche-Genentech, Novartis, Onxeo, Dachii Sankyo, MSD, Isai, Genomic Health, Ipsen, Macrogenics, Pfizer, Mylan, Lilly, Immunomedics, Sandoz. J.-P.S. declares the following financial personnal fees for activities outside the submitted work or served as consultant or advisory board/ has received Symposium and travel funding from: MSD, Lilly, Roche, Mylan, Pfizer, PFOncology, LeoPharma, Novartis, Biogaran, Astra Zeneca, Gilead, BMS. All the other authors have no conflict of interest to declare.